SCHEMBL4741309

SCHEMBL4741309

O=c1cc(O)nc(C2CCCCC2)n1Cc1ccc(Br)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.39
LMNA P02545 2/20 0.38
KDM4E B2RXH2 2/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
POLB P06746 2/20 0.37
MAPK1 P28482 1/20 0.37
BLM P54132 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
CTDSP1 Q9GZU7 1/20 0.37
TLR7 Q9NYK1 1/20 0.36
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
MAPT P10636 1/20 0.36
USP2 O75604 1/20 0.36
JAK2 O60674 1/20 0.35
JAK1 P23458 1/20 0.35
TYK2 P29597 1/20 0.35
JAK3 P52333 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4740498 0.86 CCR2 (0.41) POLBSMN1; SMN2
SCHEMBL4741265 0.85 NPC1 (0.50) KMT2AKDM4EMEN1POLBMAPK1
SCHEMBL4740381 0.85 MDM2 (0.47) KDM4EALDH1A1NPC1RAB9AALOX5AP
SCHEMBL4740407 0.85 NPC1 (0.50) KMT2AKDM4EMEN1POLBMAPK1
SCHEMBL4739114 0.83 NPC1 (0.51) KMT2ALMNAKDM4EMEN1NPC1
SCHEMBL4739117 0.79 ALDH1A1 (0.47) KMT2ALMNAKDM4EMEN1ALDH1A1
SCHEMBL4740500 0.74 APLNR (0.38) KMT2ALMNAKDM4EMEN1ALDH1A1
SCHEMBL4741289 0.72 LMNA (0.43) LMNAKDM4EMAPTUSP2
SCHEMBL4739187 0.71 EGLN3 (0.42) KMT2A
SCHEMBL4992312 0.71 EGLN3 (0.47)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008089051-A1 N-SUBSTITUTED GLYCINE DERIVATIVES: PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-07-24 WO disclosed
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2008-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors HIF1AN, EGLN2, EGLN3 KMT2A 734/4885LMNA 3270/4885KDM4E 746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.